- Glenmark receives acceptance from U.S. FDA on its IND application for GRC 54276 to proceed with a Phase 1/2, first-in-human clinical study of the molecule for the treatment of patients with advanced solid tumors and lymphomas
- Glenmark and Cediprof Announce Exclusive Distribution Agreement in the United States for US FDA Approved Mixed Amphetamines Immediate-Release Tablets
Glenmark Pharmaceuticals Ltd (GLENMARK:NSI) closed at 614.15, -2.49% below its 52-week high of 629.85, set on May 19, 2023.
348.50Jun 20 2022629.85May 19 2023
|Market cap||173.29bn INR|
|EPS (TTM)||10.53 |
|Annual div (ADY)||2.50 |
|Annual div yield (ADY)||0.41%|
|Div ex-date||Sep 12 2022|
|Div pay-date||Oct 27 2022|
Data delayed at least 15 minutes, as of Jun 02 2023 11:10 BST.